Progenics Pharmaceuticals to Host Conference Call to Review Fourth Quarter
Financial Results on March 15
TARRYTOWN, N.Y., March 8, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) announced today that it will host a conference call and
webcast to discuss its financial results for the fourth quarter 2012 on
Friday, March 15, 2013 at 8:30 a.m. ET.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001
(international) and reference conference ID 21225492. A live webcast will be
available on the Events section of the Progenics website, www.progenics.com,
and a replay will be available on the website for two weeks.
Progenics Pharmaceuticals, Inc. is discovering and developing innovative
medicines for oncology, with a pipeline that includes product candidates in
preclinical through late-stage development. Progenics' first commercial
product, Relistor^® (methylnaltrexone bromide) for opioid-induced
constipation, is marketed and in further development by Salix Pharmaceuticals,
Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co.,
Ltd. holds an exclusive license for the subcutaneous formulation. For
additional information, please visit www.progenics.com.
The Progenics Pharmaceuticals Inc. logo is available at
CONTACT: Kathleen Fredriksen
Press spacebar to pause and continue. Press esc to stop.